检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:李小刚[1] 吕新生[1] 杨连粤[1] 李学文[1] 周军[1]
机构地区:[1]湖南医科大学附属湘雅医院
出 处:《华中医学杂志》2000年第1期8-9,共2页Central China Medical Journal
基 金:湖南省科委资助课题!( No.99SSY2 0 0 2 -16)
摘 要:目的 探讨降钙素基因相关肽 (CGRP)在临床肝脏缺血预处理中的保护作用。方法 随机将 40例住院患者分组 ,1缺血预处理组 (2 2例 ) :在持续肝门阻断前先给予一个 5分钟缺血和 5分钟再灌注 ;2常规手术组 (18例 ) :按改良Pringle法常规持续阻断肝门。用放免法观察缺血预处理组和常规组持续肝门阻断前后血清 CGRP水平变化。结果 术前预处理组 CGRP值为 (2 7.41± 8.2 4) pg/ ml,常规组 (2 6 .44± 5 .2 6 ) pg/ ml,两组 CGRP值相近 (P>0 .0 5 ) ;术后预处理组 (48.19±17.98) pg/ m l,常规组 (35 .0 9± 10 .89) pg/ m l,两组均升高 (P<0 .0 1) ,但预处理组升高值与常规组比有极显著差异 (P<0 .0 1)。结论 缺血再灌注可诱发肝脏产生内源性 CGRP,缺血预处理明显增强这一作用 ,减轻了肝脏缺血再灌注损伤。Objective To study the protective effect of calcitonin gene related peptide (CGRP) in hepatic ischemic preconditioning.Methods Forty patients undergoing major hepatectomy were randomly divided into 2 groups:the ischemic preconditioning group (IPC group,n=22) which was subjected to 5 min ischemia and 5 min preconditioning before persistent hepatic inflow occlusion;the routine hepatectomy group (control group,n=18) which underwent persistent hepatic inflow occlusion by employing modified pringle’s method.Using radioimmunoassay,all the serum samples were taken for determining the levels of CGRP before and after persistent hepatic inflow occlusion. Results The preoperative serum level of CGRP was (27.41±8 24)pg/ml in IPC group and (26.44±5 26)pg/ml in control group respectively(P>0.05).Whereas the postoperative serum levels of CGRP were(48.19±17.98)pg/ml and (35.09±10.89)pg/ml respectively (P<0.01).But there was a statistical difference in CGRP between IPC group and control group (P<0 01).Conclusion Hepatic ischemia/reperfusion can induce the generation of hepatic endogenous CGRP and ischemic preconditioning can enhance this process obviously to alleviate hepatic ischemia/reperfusion injury.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.229